Mcrae Capital Management Inc. Buys 4,317 Shares of Becton, Dickinson and Company (NYSE:BDX)

Mcrae Capital Management Inc. increased its stake in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 9.3% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 50,579 shares of the medical instruments supplier's stock after acquiring an additional 4,317 shares during the quarter. Becton, Dickinson and Company makes up 2.4% of Mcrae Capital Management Inc.'s holdings, making the stock its 19th largest holding. Mcrae Capital Management Inc.'s holdings in Becton, Dickinson and Company were worth $12,195,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently modified their holdings of BDX. TCV Trust & Wealth Management Inc. lifted its position in shares of Becton, Dickinson and Company by 6.9% in the 3rd quarter. TCV Trust & Wealth Management Inc. now owns 2,313 shares of the medical instruments supplier's stock valued at $558,000 after acquiring an additional 150 shares in the last quarter. Mattern Capital Management LLC grew its stake in Becton, Dickinson and Company by 1.2% during the 3rd quarter. Mattern Capital Management LLC now owns 30,516 shares of the medical instruments supplier's stock valued at $7,357,000 after acquiring an additional 349 shares in the last quarter. DekaBank Deutsche Girozentrale increased its holdings in shares of Becton, Dickinson and Company by 2.4% in the 3rd quarter. DekaBank Deutsche Girozentrale now owns 460,083 shares of the medical instruments supplier's stock valued at $110,942,000 after purchasing an additional 10,805 shares during the period. PFG Investments LLC lifted its position in shares of Becton, Dickinson and Company by 39.2% in the third quarter. PFG Investments LLC now owns 2,539 shares of the medical instruments supplier's stock worth $612,000 after purchasing an additional 715 shares in the last quarter. Finally, Arkadios Wealth Advisors boosted its holdings in shares of Becton, Dickinson and Company by 4.4% during the third quarter. Arkadios Wealth Advisors now owns 5,885 shares of the medical instruments supplier's stock worth $1,419,000 after purchasing an additional 246 shares during the period. 86.97% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms have issued reports on BDX. Evercore ISI increased their target price on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an "outperform" rating in a research report on Tuesday, October 1st. Stifel Nicolaus boosted their target price on Becton, Dickinson and Company from $270.00 to $280.00 and gave the company a "buy" rating in a research note on Friday, July 26th. Raymond James cut their price target on Becton, Dickinson and Company from $275.00 to $270.00 and set an "outperform" rating for the company in a research note on Friday, August 2nd. StockNews.com raised Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a research note on Thursday, August 8th. Finally, Citigroup raised shares of Becton, Dickinson and Company from a "neutral" rating to a "buy" rating and raised their price objective for the company from $255.00 to $275.00 in a research report on Tuesday, October 1st. Nine research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of "Buy" and a consensus target price of $282.63.

Becton, Dickinson and Company Stock Performance

BDX stock traded down $0.49 during midday trading on Friday, hitting $238.13. 1,001,988 shares of the company traded hands, compared to its average volume of 1,380,241. Becton, Dickinson and Company has a twelve month low of $218.75 and a twelve month high of $259.92. The stock has a market capitalization of $68.82 billion, a price-to-earnings ratio of 52.45, a price-to-earnings-growth ratio of 1.79 and a beta of 0.42. The company has a quick ratio of 1.36, a current ratio of 1.85 and a debt-to-equity ratio of 0.70. The business has a 50 day simple moving average of $237.46 and a 200-day simple moving average of $235.08.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last announced its earnings results on Thursday, August 1st. The medical instruments supplier reported $3.50 EPS for the quarter, topping the consensus estimate of $3.31 by $0.19. Becton, Dickinson and Company had a net margin of 7.13% and a return on equity of 14.49%. The firm had revenue of $4.99 billion for the quarter, compared to the consensus estimate of $5.08 billion. During the same quarter last year, the firm posted $2.96 EPS. The business's quarterly revenue was up 2.3% on a year-over-year basis. As a group, equities research analysts predict that Becton, Dickinson and Company will post 13.11 earnings per share for the current year.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.